Pain
News from the FDA/CDC
Arthritis joint pain, inactivity vary greatly across U.S.
The Southeast has the highest rates of adults with severe joint pain and physical inactivity, the CDC reports.
Conference Coverage
Outpatient program successfully tackles substance use and chronic pain
MILWAUKEE – Pain and substance use issues are frequently comorbid in the military health population.
Conference Coverage
In chronic pain, catastrophizing contributes to disrupted brain circuitry
MILWAUKEE – Brief cognitive-behavioral therapy holds promise to restore functional connectivity disrupted by pain and catastrophizing.
Conference Coverage
In pain treatment, racial bias common among physician trainees
MILWAUKEE – Most residents and fellows who demonstrated racial bias did not report that race factored into treatment decisions.
News
Alvogen issues recall for mislabeled fentanyl patches
The recall was issued because a small number of cartons labeled as containing 12 mcg/h patches contained 50 mcg/h patches.
News
FDA to expand opioid labeling with instructions on proper tapering
The label changes are intended to be used when both the clinician and patient have agreed to reduce the opioid dosage.
News
Romosozumab gets FDA approval for treating osteoporosis
The pair of injections mainly works by encouraging new bone formation.
Conference Coverage
NIH’s HEAL initiative seeks coordinated effort to tackle pain, addiction
MILWAUKEE – The two aims of research under the initiative are to improve treatments for misuse and addiction, and to enhance pain management.
From the Journals
Rituximab does not improve fatigue symptoms of ME/CFS
Results from the phase 3 RituxME trial found no difference in fatigue score symptoms after 24 months.
From the Journals
Surge of gabapentinoids for pain lacks supporting evidence
Review of 54 papers for gabapentin and 30 for pregabalin finds little evidence for effective pain control in off-label uses.
From the Journals
Possible mortality risk seen with tramadol in osteoarthritis
Older patients taking tramadol for osteoarthritis had significantly higher mortality risk than did patients taking NSAIDs.